20/20 Biolabs is trading 11.9% up in after-hours at $0.31, versus the October 15 regular-session close of $0.28; its catalyst remains uncertain. - The latest listed company event was participation in the Maxim Growth Summit on October 14. - Major indexes were higher, but hotter inflation heightened rate concerns and weighed on risk sentiment; this context does not clearly explain the gain. - A local October 15 profile covered the company but reported no new market-moving announcement.